Clinical Trial Update: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy [Phase 2]

View source ↗

Summary

Phase II trial of palbociclib in metastatic urothelial carcinoma after failure of first-line chemotherapy was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Metastatic Urothelial Carcinoma (UC) | Phase 2 | Status: TERMINATED | Results posted: 2018-04-24